200 related articles for article (PubMed ID: 35401531)
1. Induced Synthesis of Mycolactone Restores the Pathogenesis of
Strong E; Hart B; Wang J; Orozco MG; Lee S
Front Immunol; 2022; 13():750643. PubMed ID: 35401531
[No Abstract] [Full Text] [Related]
2. Mycolactone gene expression is controlled by strong SigA-like promoters with utility in studies of Mycobacterium ulcerans and buruli ulcer.
Tobias NJ; Seemann T; Pidot SJ; Porter JL; Marsollier L; Marion E; Letournel F; Zakir T; Azuolas J; Wallace JR; Hong H; Davies JK; Howden BP; Johnson PD; Jenkin GA; Stinear TP
PLoS Negl Trop Dis; 2009 Nov; 3(11):e553. PubMed ID: 19936295
[TBL] [Abstract][Full Text] [Related]
3. Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo.
Adusumilli S; Mve-Obiang A; Sparer T; Meyers W; Hayman J; Small PL
Cell Microbiol; 2005 Sep; 7(9):1295-304. PubMed ID: 16098217
[TBL] [Abstract][Full Text] [Related]
4. The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR.
Bieri R; Scherr N; Ruf MT; Dangy JP; Gersbach P; Gehringer M; Altmann KH; Pluschke G
ACS Chem Biol; 2017 May; 12(5):1297-1307. PubMed ID: 28294596
[TBL] [Abstract][Full Text] [Related]
5. Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination.
Fraga AG; Martins TG; Torrado E; Huygen K; Portaels F; Silva MT; Castro AG; Pedrosa J
PLoS One; 2012; 7(3):e33406. PubMed ID: 22413022
[TBL] [Abstract][Full Text] [Related]
6. [Role of mycolactone in the nerve damage of Buruli ulcer (Mycobacterium ulcerans infection)].
En J; Ishii N; Goto M
Nihon Hansenbyo Gakkai Zasshi; 2011 Feb; 80(1):5-10. PubMed ID: 21404590
[TBL] [Abstract][Full Text] [Related]
7. Overview: Mycolactone , the Macrolide Toxin of Mycobacterium ulcerans.
Röltgen K; Pluschke G
Methods Mol Biol; 2022; 2387():105-108. PubMed ID: 34643906
[TBL] [Abstract][Full Text] [Related]
8. Evidence for an intramacrophage growth phase of Mycobacterium ulcerans.
Torrado E; Fraga AG; Castro AG; Stragier P; Meyers WM; Portaels F; Silva MT; Pedrosa J
Infect Immun; 2007 Feb; 75(2):977-87. PubMed ID: 17145944
[TBL] [Abstract][Full Text] [Related]
9. Local Cellular Immune Responses and Pathogenesis of Buruli Ulcer Lesions in the Experimental Mycobacterium Ulcerans Pig Infection Model.
Bolz M; Ruggli N; Borel N; Pluschke G; Ruf MT
PLoS Negl Trop Dis; 2016 Apr; 10(4):e0004678. PubMed ID: 27128097
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional adaptation of
Robbe-Saule M; Foulon M; Poncin I; Esnault L; Varet H; Legendre R; Besnard A; Grzegorzewicz AE; Jackson M; Canaan S; Marsollier L; Marion E
Virulence; 2021 Dec; 12(1):1438-1451. PubMed ID: 34107844
[No Abstract] [Full Text] [Related]
11. Buruli ulcer and mycolactone-producing mycobacteria.
Nakanaga K; Yotsu RR; Hoshino Y; Suzuki K; Makino M; Ishii N
Jpn J Infect Dis; 2013; 66(2):83-8. PubMed ID: 23514902
[TBL] [Abstract][Full Text] [Related]
12. Chemistry of mycolactones, the causative toxins of Buruli ulcer.
Kishi Y
Proc Natl Acad Sci U S A; 2011 Apr; 108(17):6703-8. PubMed ID: 21383136
[TBL] [Abstract][Full Text] [Related]
13. Mycolactone cytotoxicity in Schwann cells could explain nerve damage in Buruli ulcer.
En J; Kitamoto S; Kawashima A; Yonezawa S; Kishi Y; Ishii N; Goto M
PLoS Negl Trop Dis; 2017 Aug; 11(8):e0005834. PubMed ID: 28783752
[TBL] [Abstract][Full Text] [Related]
14. Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs.
Hong H; Coutanceau E; Leclerc M; Caleechurn L; Leadlay PF; Demangel C
PLoS Negl Trop Dis; 2008; 2(10):e325. PubMed ID: 18941518
[TBL] [Abstract][Full Text] [Related]
15. Mycolactone is responsible for the painlessness of Mycobacterium ulcerans infection (buruli ulcer) in a murine study.
En J; Goto M; Nakanaga K; Higashi M; Ishii N; Saito H; Yonezawa S; Hamada H; Small PL
Infect Immun; 2008 May; 76(5):2002-7. PubMed ID: 18316387
[TBL] [Abstract][Full Text] [Related]
16. Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection.
Torrado E; Adusumilli S; Fraga AG; Small PL; Castro AG; Pedrosa J
Infect Immun; 2007 Aug; 75(8):3979-88. PubMed ID: 17517872
[TBL] [Abstract][Full Text] [Related]
17. A newly discovered mycobacterial pathogen isolated from laboratory colonies of Xenopus species with lethal infections produces a novel form of mycolactone, the Mycobacterium ulcerans macrolide toxin.
Mve-Obiang A; Lee RE; Umstot ES; Trott KA; Grammer TC; Parker JM; Ranger BS; Grainger R; Mahrous EA; Small PL
Infect Immun; 2005 Jun; 73(6):3307-12. PubMed ID: 15908356
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence.
Mve-Obiang A; Lee RE; Portaels F; Small PL
Infect Immun; 2003 Feb; 71(2):774-83. PubMed ID: 12540557
[TBL] [Abstract][Full Text] [Related]
19. On the origin of Mycobacterium ulcerans, the causative agent of Buruli ulcer.
Doig KD; Holt KE; Fyfe JA; Lavender CJ; Eddyani M; Portaels F; Yeboah-Manu D; Pluschke G; Seemann T; Stinear TP
BMC Genomics; 2012 Jun; 13():258. PubMed ID: 22712622
[TBL] [Abstract][Full Text] [Related]
20. Investigation of wild-type and mycolactone-negative mutant Mycobacterium ulcerans on skeletal muscle: IGF-1 protects against mycolactone-induced muscle catabolism.
Dufresne SS; Frenette J
Am J Physiol Regul Integr Comp Physiol; 2013 May; 304(9):R753-62. PubMed ID: 23485865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
